Search

Your search keyword '"Potschger, Ulrike"' showing total 7 results
Start Over Author "Potschger, Ulrike"
7 results on '"Potschger, Ulrike"'

1. Frequency and prognostic impact of alk amplifications and mutations in the european neuroblastoma study group (siopen) high-risk neuroblastoma trial (hr-nbl1)

Author

Bellini, Angela, Potschger, Ulrike, Bernard, Virginie, Lapouble, Eve, Baulande, Sylvain, Ambros, Peter F., Auger, Nathalie, Beiske, Klaus, Bernkopf, Marie, Betts, David R., Bhalshankar, Jaydutt, Bown, Nick, De Preter, Katleen, Clement, Nathalie, Combaret, Valerie, De Mora, Jaime Font, George, Sally L., Jimenez, Irene, Jeison, Marta, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Morini, Martina, Muhlethaler-Mottet, Annick, Noguera, Rosa, Pierron, Gaelle, Rossing, Maria, Taschner-Mandl, Sabine, Van Roy, Nadine, Vicha, Ales, Chesler, Louis, Balwierz, Walentyna, Castel, Victoria, Elliott, Martin, Kogner, Per, Laureys, Genevieve, Luksch, Roberto, Malis, Josef, Popovic-Beck, Maja, Ash, Shifra, Delattre, Olivier, Valteau-Couanet, Dominique, Tweddle, Deborah A., Ladenstein, Ruth, Schleiermacher, Gudrun, Bellini, Angela, Potschger, Ulrike, Bernard, Virginie, Lapouble, Eve, Baulande, Sylvain, Ambros, Peter F., Auger, Nathalie, Beiske, Klaus, Bernkopf, Marie, Betts, David R., Bhalshankar, Jaydutt, Bown, Nick, De Preter, Katleen, Clement, Nathalie, Combaret, Valerie, De Mora, Jaime Font, George, Sally L., Jimenez, Irene, Jeison, Marta, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Morini, Martina, Muhlethaler-Mottet, Annick, Noguera, Rosa, Pierron, Gaelle, Rossing, Maria, Taschner-Mandl, Sabine, Van Roy, Nadine, Vicha, Ales, Chesler, Louis, Balwierz, Walentyna, Castel, Victoria, Elliott, Martin, Kogner, Per, Laureys, Genevieve, Luksch, Roberto, Malis, Josef, Popovic-Beck, Maja, Ash, Shifra, Delattre, Olivier, Valteau-Couanet, Dominique, Tweddle, Deborah A., Ladenstein, Ruth, and Schleiermacher, Gudrun

Abstract

PURPOSE In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. MATERIALS AND METHODS Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n 5 330), ALK mutational profile (n 5 191), or both (n 5 571). RESULTS Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n 5 41] 28% [95% CI, 15 to 42]; no-ALKa [n 5 860] 51% [95% CI, 47 to 54], [P , .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (. 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P , .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa [n 5 19], 26% [95% CI, 10 to 47], clonal ALKm[n565] 33% [95% CI, 21 to 44], subclonal ALKm(n522) 48% [95% CI, 26 to 67], and no alteration [n 5 465], 51% [95% CI, 46 to 55], respectively; P 5 .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P , .001), ALKa (HR, 2.38; P 5 .004), and clonal ALKm (HR, 1.77; P 5 .001) were independent predictors of poor outcome. CONCLUSION Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integr

Published
2021

2. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project

Author

Moreno, Lucas, primary, Guo, Dongjing, additional, Irwin, Meredith S., additional, Berthold, Frank, additional, Hogarty, Michael, additional, Kamijo, Takehiko, additional, Morgenstern, Daniel, additional, Pasqualini, Claudia, additional, Ash, Shifra, additional, Potschger, Ulrike, additional, Ladenstein, Ruth, additional, Valteau‐Couanet, Dominique, additional, Cohn, Susan L., additional, Pearson, Andrew D.J., additional, and London, Wendy B., additional

Published
2020
Full Text
View/download PDF

4. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project.

Author

Moreno, Lucas, Guo, Dongjing, Irwin, Meredith S., Berthold, Frank, Hogarty, Michael, Kamijo, Takehiko, Morgenstern, Daniel, Pasqualini, Claudia, Ash, Shifra, Potschger, Ulrike, Ladenstein, Ruth, Valteau‐Couanet, Dominique, Cohn, Susan L., Pearson, Andrew D.J., and London, Wendy B.

Published
2021
Full Text
View/download PDF

5. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project

Author

Moreno, Lucas, Guo, Dongjing, Irwin, Meredith S., Berthold, Frank, Hogarty, Michael, Kamijo, Takehiko, Morgenstern, Daniel, Pasqualini, Claudia, Ash, Shifra, Potschger, Ulrike, Ladenstein, Ruth, Valteau-Couanet, Dominique, Cohn, Susan L., Pearson, Andrew D. J., London, Wendy B., Moreno, Lucas, Guo, Dongjing, Irwin, Meredith S., Berthold, Frank, Hogarty, Michael, Kamijo, Takehiko, Morgenstern, Daniel, Pasqualini, Claudia, Ash, Shifra, Potschger, Ulrike, Ladenstein, Ruth, Valteau-Couanet, Dominique, Cohn, Susan L., Pearson, Andrew D. J., and London, Wendy B.

Abstract

Background Long-term outcome remains poor for children with high-risk neuroblastoma (five-year overall survival [OS] similar to 50%). Our objectives were to (a) identify prognostic biomarkers and apply them in a nomogram to identify the subgroup of ultra-high-risk patients at highest risk of disease progression/death, for whom novel frontline therapy is urgently needed; and (b) validate the nomogram in an independent cohort. Methods A total of 1820 high-risk patients (>= 18 months old with metastatic neuroblastoma), diagnosed 1998-2015, from the International Neuroblastoma Risk Groups (INRG) Data Commons were analyzed in a retrospective cohort study. Using multivariable Cox regression of OS from diagnosis, a nomogram was created from prognostic biomarkers to predict three-year OS. External validation was performed using the SIOPEN HR-NBL1 trial cohort (n = 521), evidenced by receiver operating characteristic curves. Results The nomogram, including MYCN status (P < 0.0001), lactate dehydrogenase (LDH) (P = 0.0007), and presence of bone marrow metastases (P = 0.004), had robust performance and was validated. Applying the nomogram at diagnosis (a) gives prognosis of an individual patient and (b) identifies patients predicted to have poor outcome (three-year OS was 30% +/- 5% for patients with a nomogram score of > 82 points; 58% +/- 1% for those <= 82 points). Median follow-up time was 5.5 years (range, 0-14.1). Conclusions In high-risk neuroblastoma, a novel, publicly available nomogram using prognostic biomarkers (MYCN status, LDH, presence of bone marrow metastases; ) has the flexibility to apply a clinically suitable and context-specific cutoff to identify patients at highest risk of death. This will facilitate testing urgently needed new frontline treatment options to improve outcome for these children.

6. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project

Author

Moreno, Lucas, Guo, Dongjing, Irwin, Meredith S., Berthold, Frank, Hogarty, Michael, Kamijo, Takehiko, Morgenstern, Daniel, Pasqualini, Claudia, Ash, Shifra, Potschger, Ulrike, Ladenstein, Ruth, Valteau-Couanet, Dominique, Cohn, Susan L., Pearson, Andrew D. J., London, Wendy B., Moreno, Lucas, Guo, Dongjing, Irwin, Meredith S., Berthold, Frank, Hogarty, Michael, Kamijo, Takehiko, Morgenstern, Daniel, Pasqualini, Claudia, Ash, Shifra, Potschger, Ulrike, Ladenstein, Ruth, Valteau-Couanet, Dominique, Cohn, Susan L., Pearson, Andrew D. J., and London, Wendy B.

Abstract

Background Long-term outcome remains poor for children with high-risk neuroblastoma (five-year overall survival [OS] similar to 50%). Our objectives were to (a) identify prognostic biomarkers and apply them in a nomogram to identify the subgroup of ultra-high-risk patients at highest risk of disease progression/death, for whom novel frontline therapy is urgently needed; and (b) validate the nomogram in an independent cohort. Methods A total of 1820 high-risk patients (>= 18 months old with metastatic neuroblastoma), diagnosed 1998-2015, from the International Neuroblastoma Risk Groups (INRG) Data Commons were analyzed in a retrospective cohort study. Using multivariable Cox regression of OS from diagnosis, a nomogram was created from prognostic biomarkers to predict three-year OS. External validation was performed using the SIOPEN HR-NBL1 trial cohort (n = 521), evidenced by receiver operating characteristic curves. Results The nomogram, including MYCN status (P < 0.0001), lactate dehydrogenase (LDH) (P = 0.0007), and presence of bone marrow metastases (P = 0.004), had robust performance and was validated. Applying the nomogram at diagnosis (a) gives prognosis of an individual patient and (b) identifies patients predicted to have poor outcome (three-year OS was 30% +/- 5% for patients with a nomogram score of > 82 points; 58% +/- 1% for those <= 82 points). Median follow-up time was 5.5 years (range, 0-14.1). Conclusions In high-risk neuroblastoma, a novel, publicly available nomogram using prognostic biomarkers (MYCN status, LDH, presence of bone marrow metastases; ) has the flexibility to apply a clinically suitable and context-specific cutoff to identify patients at highest risk of death. This will facilitate testing urgently needed new frontline treatment options to improve outcome for these children.

7. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease.

Author

Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, Preuner S, Futterknecht B, Lawitschka A, Peters C, Potschger U, and Gadner H

Subjects
Adenoviridae genetics, Adenovirus Infections, Human epidemiology, Adenovirus Infections, Human etiology, Adolescent, Adult, Bone Marrow Transplantation methods, Bone Marrow Transplantation mortality, Child, Child, Preschool, Humans, Incidence, Infant, Molecular Diagnostic Techniques, Polymerase Chain Reaction methods, Polymerase Chain Reaction standards, Risk Factors, Survival Analysis, Transplantation, Homologous, Viral Load methods, Adenovirus Infections, Human diagnosis, Bone Marrow Transplantation adverse effects, DNA, Viral blood
Abstract

Adenovirus (AdV) infection in the course of allogeneic stem cell transplantation (SCT) is associated with high transplant-related morbidity and mortality. Disseminated AdV disease is lethal in most instances. Early detection of AdV infection and identification of patients carrying a high risk of disseminated disease therefore remain a major challenge. In view of the large number of existing AdV types, we have established real-time polymerase chain reaction (PCR) assays permitting sensitive detection and quantification of all 51 currently known human AdV serotypes. In a series of 132 consecutive pediatric patients undergoing SCT, more than 5000 samples derived from peripheral blood (PB), stool, urine, and throat were screened for adenovirus infection by PCR during the posttransplantation period. Thirty-six patients (27%) tested positive by PCR, revealing AdV types of the subgenera A, B, C, D, and F. Except for enteritis in some patients with AdV positivity in stool, detection of the virus at sites other than PB was not associated with clinical signs of virus disease, and transplant-related mortality was not significantly different from AdV-negative patients. By contrast, 82% of patients who had detectable AdV in PB died from infectious complications (P <.001). Monitoring of PB specimens by real-time PCR permitted early diagnosis of invasive AdV infection in all instances. In patients who developed disseminated AdV disease, detection of the virus in PB preceded onset of clinical symptoms by a median of more than 3 weeks. The observation of AdV in peripheral blood may therefore serve as a basis for early initiation of preemptive antiviral treatment.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results